Inflammation and Immunosuppression Flashcards
(303 cards)
Omalizumab
mAb against IgE, used to treat dermatographic urticarial and allergic asthma
Binds to Cepsilon3 region of IgE (heavy chain) so prevents IgE binding to FcepsilonRI
Built on an IgG framework so doesn’t activate FcepsilonRI itself
Injection every 2-4w
Sodium cromoglyate
Reduces Ca2+ influx into mast cells, prevents degranulation. In eye drops for hayfever and used for mastocytosis, and occasionally asthma
Salbutamol
Short-acting beta2 adrenoceptor agonist, used as needed in treatment of asthma
Maximum effect in 30min
Duration of action 3-5hrs
Formoterol
Long-acting beta2 adrenoceptor agonist, prophylactic use in the treatment of asthma
Duration of action 8-12 hours
Long lipophilic tail enables it to be incorporated into the plasma membrane, which acts as a drug reservoir, and also the long tail binds to an extra binding site on the beta2 aidrenoceptor itself
Theophylline
PDE inhibitor producing increased cAMP, used prophylactically in treatment of asthma/COPD
Mepyramine
1st generation H1 receptor antagonist, crosses BBB causes drowsiness, used topically to treat insect bites.
Terfenadine
2nd gen H1 antagonist, inhibited hERG causing long QT syndrome and so no longer used. Prodrug metabolised by Cytochrome p450 3A4 to fexofenadine (the active compound).
Fexofenadine
3rd gen anti-histamine. Non-drowsy, no cardiac side effects. Used to treat hayfever and urticaria.
Loratidine
3rd gen anti-histamine, non-drowsy, used to treat hayfever and urticaria.
Adrenaline
Used to treat anaphylactic shock
Hydrocortisone
Corticosteroid used as anti-inflammatory. Short t1/2 <24h
Inhibits neutrophil degranulation
Imatinib
RTK inhibitor used in treatment of human mastocytosis. Ineffective in treatment of people with common D816V c-kit mutation.
Oclacitinib
Treatment of atopic dermatitis in dogs. Inhibits JAK, greatest specificity for JAK1, which is common to many signalling pathways associated with allergic skin diseases - so lowers proinflammatory signalling.
Proglumide
CCK2 receptor antagonist that produces an inhibition of histamine release from ECL cells
Cimetidine
H2 receptor antagonist, inhibits cytochrome p450, replaced by ranitidine
Ranitidine
H2 receptor antagonist, used in treatment of peptic ulcers
Omeprazole
PPI used in treatment of peptic ulcers.
Clarithromycin
Macrolide antibiotic used to eradicate H. pylori
Misoprostol
Synthetic PGE1 analogue acts to decrease ECL histamine release in treating peptic ulcers.
Arthrotec
Combination of misoprostol and diclofenac, used in chronic treatment of rheumatoid arthritis to prevent peptic ulcer formation. Misoprostol acts as a prophylactic agent against NSAID-induced ulceration.
Diclofenac
NSAID used in treating chronic inflammation
Ecallantide
Kallikrein inhibitor used in the treatment of HAE.
Tanezumab
Anti-NGF antibody, in clinical trials for treating OA
Bufexamac
LTA4 hydrolase inhibitor, can be used as an anti-inflammatory agent